With a focus on resolving various cardiovascular and cerebrovascular diseases, we have built a multi-level product portfolio. Compound Danshen Dripping Pills is our flagship product among an array of related products such as Yangxueqingnao (granules/pills), Qishenyiqi Dripping Pills, and injections such as Recombinant Human Prourokinase, Yiqi Fumai (freeze-dried), and Salvia Miltiorrhiza Polyphenolic Acid. The portfolio comprises products that are part of a comprehensive therapy for treating cardiovascular and cerebrovascular diseases. We have made significant efforts in the research and development of new Traditional Chinese Medicine (TCM) products and to improve the product life-cycle management. Our current products are focused on hyperlipidemia, platelet aggregation, heart failure, stroke as well as post-stroke recovery. We are also striving to fill the current void in the availability of stem-cell products for the treatment of cardiovascular and cerebrovascular diseases and build a comprehensive product portfolio suited for the prevention, treatment and recovery of such diseases. We are also working to provide a comprehensive solution to patients suffering from different stages of cardiovascular and cerebrovascular diseases.